Aberrant type I and type III collagen gene expression in human breast cancer in vivo

Increased synthesis and degradation of extracellular matrix components are associated with breast cancer development. This study evaluated type I and type III procollagen mRNA expression and the corresponding protein synthesis and maturation, as well as the tissue distribution of these collagens, in benign breast lesions, infiltrating ductal carcinomas, and their metastases by in situ hybridization and immunohistochemistry. In the benign lesions, the type I and type III collagen bundles were regularly organized and the expression of the corresponding mRNA was weak, indicating a relatively slow collagen turnover. In the malignant tumours, increased expression of type I and type III procollagen mRNAs was observed in the fibroblastic cells of the stroma; the malignant epithelial cells did not participate. The staining of corresponding newly‐synthesized pN‐collagens showed aberrant bundles in the invasive front of the malignant tumours. Newly‐synthesized type I and type III procollagens were occasionally observed in fibroblastic cells, particularly in grade 2 and grade 3 tumours. Metastases of breast carcinoma resembled poorly differentiated primary tumours with respect to their collagen synthesis and deposition. The increased synthesis of fibrillar type I and type III procollagens may serve as a pathway for tumour invasion. The enhanced synthesis is associated with the formation of aberrant collagen bundles, which may be more readily degradable and may thus facilitate breast tumour invasion. Copyright © 1998 John Wiley & Sons, Ltd.

[1]  J. Risteli,et al.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. , 1993, Clinical chemistry.

[2]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  M. Al-Adnani,et al.  Inappropriate production of collagen and prolyl hydroxylase by human breast cancer cells in vivo. , 1975, British Journal of Cancer.

[4]  Gary R. Grotendorst,et al.  Increased content of Type V Collagen in desmoplasia of human breast carcinoma. , 1982, The American journal of pathology.

[5]  A. Skubitz,et al.  Tumor cell invasion, matrix metalloproteinases, and the dogma. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[6]  J. Rosenbloom,et al.  Molecular cloning and carboxyl-propeptide analysis of human type III procollagen. , 1984, Nucleic acids research.

[7]  J. Risteli,et al.  Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. , 1996, The American journal of pathology.

[8]  T. Hurskainen,et al.  Simultaneous expression of 70 kilodalton type IV collagenase and type IV collagen alpha 1 (IV) chain genes by cells of early human placenta and gestational endometrium. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[9]  R. Timpl,et al.  Collagen Fibrillogenesis in Human Skin a , 1985, Annals of the New York Academy of Sciences.

[10]  J. Risteli,et al.  Immunohistochemical study of type I collagen and type I pN‐collagen in benign and malignant ovarian neoplasms , 1995, Cancer.

[11]  J L Kelsey,et al.  Breast cancer: magnitude of the problem and descriptive epidemiology. , 1993, Epidemiologic reviews.

[12]  P. Sommer,et al.  Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. , 1997, The American journal of pathology.

[13]  J. Foidart,et al.  Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. , 1993, British Journal of Cancer.

[14]  L. Liotta,et al.  Tumor invasion and the extracellular matrix. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[15]  L. Garfinkel,et al.  Changing trends: An overview of breast cancer incidence and mortality , 1994, Cancer.

[16]  J. Risteli,et al.  Immunoassay for intact amino-terminal propeptide of human type I procollagen. , 1996, Clinical chemistry.

[17]  J. Risteli,et al.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. , 1988, Clinical chemistry.

[18]  M J Bissell,et al.  Involvement of extracellular matrix constituents in breast cancer. , 1995, Seminars in cancer biology.

[19]  C. Clavel,et al.  Detection by in situ hybridization of messenger RNAs of collagen types I and IV in murine mammary cancer , 1989, International journal of cancer.

[20]  J. K. Makela,et al.  Human pro alpha 1(I) collagen: cDNA sequence for the C-propeptide domain , 1988, Nucleic Acids Res..

[21]  R. Stern,et al.  The matrix of human breast tumor cells is mitogenic for fibroblasts. , 1984, The American journal of pathology.

[22]  K. Kühn The classical collagens : types I, II and III , 1987 .

[23]  J. Risteli,et al.  Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. , 1997, Cancer research.

[24]  J. Risteli,et al.  Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study , 1993, Cancer.

[25]  J. Foekens,et al.  Stromal influences on breast cancer cell growth. , 1992, British Journal of Cancer.

[26]  M L Tanzer,et al.  Cross-Linking of Collagen , 1973, Science.